Evaluation of Clinical Relevance and Biological Effects of Antirituximab Antibodies in Patients With Pemphigus

Authors:

Abstract
Rituximab (RTX), a chimeric monoclonal antibody (Ab) anti-CD20, is approved as a first-line treatment for moderate-to-severe pemphigus vulgaris. Its superiority compared with a conventional regimen of corticosteroids and mycophenolate mofetil has been demonstrated.1,2 The rate of relapse after RTX treatment increases over time. In the Ritux3 trial, around 25% of patients experienced relapse within the first 12 months, and some patients relapsed later on, suggesting the potential interest of maintenance infusions of RTX (NCT00784589). Multiple maintenance infusions have been associated with good clinical outcomes,3 although this systematic retreatment is not completely satisfactory because around 40% of patients do not experience relapse, even in the long term.1,2,4,5

This publication has 21 references indexed in Scilit: